FDA re­ject­ed Out­look Ther­a­peu­tic­s' Lu­cen­tis ri­val, and the com­pa­ny's stock plunged

The FDA has re­ject­ed Out­look Ther­a­peu­tics’ oph­thalmic for­mu­la­tion of be­va­cizum­ab for wet AMD, an eye dis­or­der that can cause blurred vi­sion or blind spots.

In their com­plete re­sponse let­ter, reg­u­la­tors not­ed “sev­er­al CMC is­sues, open ob­ser­va­tions from pre-ap­proval man­u­fac­tur­ing in­spec­tions, and a lack of sub­stan­tial ev­i­dence,” Out­look said Wednes­day.

The com­pa­ny’s stock $OTLK plunged more than 83% Wednes­day morn­ing to $0.23 per share.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER